Puma Biotechnology

PBYI

Market cap $368M

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 31,625 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity award.

PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.

Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.

Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.

Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Puma Biotech (PBYI) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.43 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of inducement awards to two new hires in January 2026, as required under Nasdaq Listing Rule 5635(c)(4).